Changes in T cell receptor repertoire associated with graft-versus-tumor effect and graft-versus-host disease in patients with relapsed multiple myeloma after donor lymphocyte infusion

Bone Marrow Transplantation

Volumn 25, Issue 6, 2000, Pages 623-632

  Orsini, E ^a   Alyea, E P ^a   Schlossman, R ^a   Canning, C ^a   Soiffer, R J ^a   Chillemi, A ^a   Neuberg, D ^a,b   Anderson, K C ^a   Ritz, J ^a,c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Donor lymphocyte infusions; Graft versus myeloma; GVHD; Multiple myeloma; V repertoire

Indexed keywords

CD4 ANTIGEN; PARAPROTEIN; T LYMPHOCYTE RECEPTOR;

ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; BLOOD SAMPLING; CASE REPORT; CLINICAL TRIAL; FEMALE; GENE AMPLIFICATION; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HUMAN; HUMAN CELL; LEUKAPHERESIS; LYMPHOCYTE CLONE; MALE; MULTIGENE FAMILY; MULTIPLE MYELOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

EID: 0034019523     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1702187     Document Type: Article

References (37)

1. Weiden P, Sullivan K, Flournoy N et al. Anti-leukemia effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. New Engl J Med 1981; 304: 1529-1533.
2. Horowitz MM, Gale RP, Sondel PM et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990; 75: 555-562.
3. Sullivan KM, Weiden PL, Storb R et al. Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia (published erratum appears in Blood 1989; 74: 1180). Blood 1989; 73: 1720-1728.
4. + Tc1 and Tc2 populations in graft-versus-leukemia effect and graft-versus-host disease. J Immunol 1996; 157: 4811-4821.
5. Kolb HJ, Mittermuller J, Clem C et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990; 76: 2462-2465.
6. Collins R, Shpilberg O, Drobyski W et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 1997; 15: 433-444.
7. Kolb HJ, Schattenberg A, Goldman JM et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood 1995; 86: 2041-2050.
8. Slavin S, Naparstek E, Nagler A et al. Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation. Blood 1996; 87: 2195-2204.
9. Antin JH. Graft-versus-leukemia: no longer an epiphenomenon. Blood 1993; 82: 2273-2277.
10. Mackinnon S, Papadopoulos EB, Carabasi MH et al. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. Blood 1995; 86: 1261-1268.
11. Giralt S, Hester J, Huh Y et al. CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation. Blood 1995; 86: 4337-4343.
12. + donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant. Blood 1998; 91: 3671-3680.
13. Bensinger WI, Buckner CD, Anasetti C et al. Allogeneic marrow transplantation for multiple myeloma: an analysis of risk factors on outcome. Blood 1996; 88: 2787-2793.
14. Barlogie B, Jagannath S, Vesole DH et al. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood 1997; 89: 789-793.
15. Vesole DH, Tricot G, Jagannath S et al. Autotransplants in multiple myeloma: what have we learned? Blood 1996; 88: 838-847.
16. Attal M, Harousseau JL, Stoppa AM et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. New Engl J Med 1996; 335: 91-97.
17. Anderson KC, Barut BA, Ritz J et al. Monoclonal antibody-purged autologous bone marrow transplantation therapy for multiple myeloma. Blood 1991; 77: 712-720.
18. Bjorkstrand BB, Ljungman P, Svensson H et al. Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: a retrospective case-matched study from the European Group for Blood and Marrow Transplantation. Blood 1996; 88: 4711-4718.
19. Tricot G, Vesole DH, Jagannath S et al. Graft-versus-myeloma effect: proof of principle. Blood 1996; 87: 1196-1198.
20. Bertz H, Burger JA, Kunzmann R et al. Adoptive immunotherapy for relapsed multiple myeloma after allogeneic bone marrow transplantation (BMT): evidence for a graft-versus-myeloma effect. Leukemia 1997; 11: 281-283.
21. Verdonck LF, Lokhorst HM, Dekker AW et al. Graft-versus-myeloma effect in two cases (see comments). Lancet 1996; 347: 800-801.
22. Lokhorst H, Schattenberg A, Cornelissen J et al. Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation. Blood 1997; 90: 4206-4211.
23. Dietrich PY, Caignard A, Lim A et al. In vivo T-cell clonal amplification at time of acute graft-versus-host disease. Blood 1994; 84: 2815-2820.
24. Gaschet J, Lim A, Liem L et al. Acute graft versus host disease due to T lymphocytes recognizing a single HLA-DPB1* 0501 mismatch. J Clin Invest 1996; 98: 100-107.
25. Gaschet J, Trevino MA, Cherel M et al. HLA-target antigens and T-cell receptor diversity of activated T cells invading the skin during acute graft-versus-host disease. Blood 1996; 87: 2345-2353.
26. Claret E, Alyea E, Orsini E et al. Characterization of T cell repertoire in patients with graft-versus-leukemia following donor lymphocyte infusion. J Clin Invest 1997; 100: 855-866.
27. + T-cell repertoire that are not immediately restored by antiviral or immune-based therapies. Nature Med 1997; 3: 533-540.
28. Choi YW, Kotzin B, Herron L et al. Interaction of Staphylococcus aureus toxin 'superantigens' with human T cells. Proc Natl Acad Sci USA 1989; 86: 8941-8945.
29. Puisieux I, Even J, Pannetier C et al. Oligoclonality of tumor-infiltrating lymphocytes from human melanomas. J Immunol 1994; 153: 2807-2818.
30. Pannetier C, Cochet M, Darche S et al. The sizes of the CDR3 hypervariable regions of the murine T-cell receptor beta chains vary as a function of the recombined germ-line segments. Proc Natl Acad Sci USA 1993; 90: 4319-4323.
31. Gorski J, Yassai M, Zhu X et al. Circulating T cell repertoire complexity in normal individuals and bone marrow recipients analyzed by CDR3 size spectratyping. Correlation with immune status. J Immunol 1994; 152: 5109-5119.
32. Gratwohl A, Hermans J, Apperley J et al. Acute graft-versus-host disease: grade and outcome in patients with chronic myelogenous leukemia. Working Party Chronic Leukemia of the European Group for Blood and Marrow Transplantation. Blood 1995; 86: 813-818.
33. Enright H, Davies SM, De For T et al. Relapse after non-T-cell-depleted allogeneic bone marrow transplantation for chronic myelogenous leukemia: early transplantation, use of an unrelated donor, and chronic graft-versus-host disease are protective. Blood 1996; 88: 714-720.
34. Gahrton G, Tura S, Ljungman P et al. Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma. J Clin Oncol 1995; 13: 1312-1322.
35. Kwak L, Taub D, Duffey P et al. Transfer of myeloma idiotype-specific immunity from an actively immunised marrow donor. Lancet 1995; 345: 1016-1020.
36. van Baren N, Brasseur F, Godelaine D et al. Genes encoding tumor-specific antigens are expressed in human myeloma cells. Blood 1999; 94: 1156-1164.
37. Mutis T, Gillespie G, Schrama E et al. Tetrameric HLA class I-minor histocompatibility antigen peptide complexes demonstrate minor histocompatibility antigen-specific cytotoxic T lymphocytes in patients with graft-versus-host disease. Nature Med 1999; 5: 839-842.